Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Parkinson disease Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient, AND The treatment must be as adjunctive therapy to a levodopa-decarboxylase inhibitor combination, AND Patient must be experiencing fluctuations in motor function due to end-of-dose effect. Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
“Entacapone decreases the metabolic loss of levodopa to 3-O-methyldopa (3-OMD) by inhibiting the enzyme COMT. This leads to a more sustained plasma concentration of levodopa with no delay in the time to reach the peak concentration.”
“Approximately 92% of the dose is eliminated during the β-phase with a short elimination half-life of 30 minutes.”
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Data from in vitro studies using human liver microsomal preparations indicate that entacapone inhibits cytochrome P450 2C9 (IC50 ~4 μM). Entacapone showed little or no inhibition of other types of P450 isoenzymes (CYP1A2, CYP2A6, CYP2D6, CYP2E1, CYP3A and CYP2C19)”